Premium
Oral isotretinoin as the most effective treatment in folliculitis decalvans: a retrospective comparison of different treatment regimens in 28 patients
Author(s) -
Tietze J.K.,
Heppt M.V.,
Preußen A.,
Wolf U.,
Ruzicka T.,
Wolff H.,
Sattler E.C.
Publication year - 2015
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.13052
Subject(s) - medicine , isotretinoin , folliculitis , dermatology , clarithromycin , dapsone , rifampicin , antibiotics , clindamycin , acne , surgery , retrospective cohort study , tuberculosis , helicobacter pylori , pathology , microbiology and biotechnology , biology
Background Folliculitis decalvans leads to scarring alopecia through inflammatory destruction of the hair follicle. Currently, antibiotics are most commonly used to treat this disease. However, treatment regimens with antibiotics feature a high relapse rate and encourage the development of resistant bacteria. Objective To evaluate the outcome of different treatment options for folliculitis decalvans. Methods Retrospective study to compare the efficacy of different treatment regimens in 28 patients with folliculitis decalvans. Results The success of treatment with clindamycin and rifampicin, clarithromycin, dapsone and isotretinoin was analysed. The evaluation of the combination of clindamycin and rifampicin showed the lowest success rate in achieving long‐term remission, since 80% of the patients relapsed shortly after end of treatment. Clarithromycin and dapsone were more successful with long‐term and stable remission rates of 33% and 43% respectively. Treatment with isotretinoin was the most successful oral treatment in our analysis with 90% of the patients experiencing stable remission during and up to two years after cessation of the treatment. Conclusion The common use of antibiotics as first‐line therapy in folliculitis decalvans needs to be re‐evaluated critically and oral isotretinoin should be considered as valid treatment alternative.